Lakefront Biotherapeutics NV
LKFT Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$32.28
KIRA · Stoqly’s AI analyst, in plain words
- Lakefront Biotherapeutics NV had $1.3B of revenue in fiscal 2025, up 320.6% on the year before. Over five years, revenue changed +18.1% a year on average.
- Its operating margin was 26.5%, up 94.9 pts: of every 100 in sales, about 27 is left after running the business.
- Lakefront Biotherapeutics NV made $362M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 17.8% a year.
- Free cash flow was −$306M in fiscal 2025, −24.4% of revenue. At that burn of $306M a year, its $103M of cash and short-term investments would last about 0.3 years.
Market cap
$2.1B
P/E
5.9x
Revenue
$1.3B
Net income
$362M
Free cash flow
−$306M
Operating margin
26.5%
Lakefront Biotherapeutics NV in 30 seconds · fiscal 2025
Are sales growing?
+320.6%
Yes. Sales grew 320.6% last year.
Does it make a profit?
28.9%
Yes. It keeps 28.9% of every sale as profit.
How long would its cash last?
0.3 yrs
Not long. It burns $306M a year and holds $103M, under a year at that pace, so it may need new money soon.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
5.9x
One share costs 5.9 times its yearly profit per share.
What Lakefront Biotherapeutics NV does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 26, 2026
- Legal name
- Lakefront Biotherapeutics NV
- CIK
- 0001421876
Lakefront Biotherapeutics NV · LKFT · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $277M | $254M | $259M | $298M | $1.3B |
| Revenue growth | −49.1% | −8.5% | 2.2% | 15.0% | 320.6% |
| Gross margin | 99.3% | 95.0% | — | 87.4% | 97.3% |
| Operating margin | −73.2% | −54.3% | −36.8% | −68.3% | 26.5% |
| Net income | −$122M | −$229M | $229M | $80.1M | $362M |
| Net margin | −44.0% | −90.4% | 88.3% | 26.9% | 28.9% |
| Diluted EPS | −$1.87 | −$3.49 | $3.47 | $1.21 | $5.49 |
| Cash | |||||
| Cash from operations | −$596M | −$526M | −$439M | −$346M | −$290M |
| Capital expenditure | $64.1M | $28.8M | $20.2M | $18.1M | $15.5M |
| Free cash flow | −$660M | −$555M | −$459M | −$364M | −$306M |
| FCF margin | −238.1% | −218.8% | −177.2% | −122.2% | −24.4% |
| Share count change | 0.7% | 0.3% | 0.3% | 0.0% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $2.5B | $542M | $184M | $66.7M | $103M |
| Shareholders' equity | $3.0B | $2.7B | $3.1B | $3.0B | $3.8B |
| Current ratio | 8.6x | 8.1x | 9.0x | 10.0x | 20.1x |
| Interest coverage | −14.8x | −19.0x | −49.9x | −206.7x | 285.3x |
| Returns and quality | |||||
| Return on equity | −3.9% | −8.1% | 7.9% | 2.6% | 10.6% |
| Return on tangible equity | −4.2% | −9.3% | 8.0% | 2.9% | 9.5% |
| Piotroski F-score | 2 | 1 | 4 | 3 | 6 |
| Altman Z'' | 6.1 | 5.8 | 6.7 | 6.8 | 26.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lakefront Biotherapeutics NV · LKFT · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $32.28 a share, the company is worth $2.1B: 5.9 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001421876). Latest version: stoqly.net/companies/lkft. Data updated November 1, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.